Europe/Argentina, sampled during winter, and infected with HIV through nonhomosexual exposure were at higher odds of having low 25(OH)D levels, whereas persons receiving protease inhibitors were at lower odds. Compared to those in the lowest 25(OH)D tertile (<12 ng/ml), those in the middle (12-20) and higher (>20) tertiles had a significantly lower risk of clinical progression during subsequent follow-up. Adjusted incidence rate ratios for all-cause mortality were 0.68 (95% CI 0.47-0.99, P ¼ 0.045) and 0.56 (95% CI 0.37-0.83, P ¼ 0.0039), and for AIDS events were 0.58 (95% CI 0.39-0.87, P ¼ 0.0086) and 0.61 (95% CI 0.40-0.93, P ¼ 0.020), for the middle and higher tertiles, respectively. There was a similar, nonsignificant reduced incidence of non-AIDS events in the middle and higher tertiles.
Introduction
In the general population, vitamin D insufficiency, assessed by the measurement of serum 25-hydroxyvitamin D [25(OH)D], is frequent. There is increasing agreement that 25(OH)D levels below 30 ng/ml reflect insufficiency [1] [2] [3] [4] [5] [6] . This threshold was initially based on the relationship observed in apparently healthy populations between 25(OH)D serum levels and parathyroid hormone, whereas it now more consistently relies on the 25(OH)D concentrations obtained during randomized trials in which vitamin D has been shown to reduce the relative risk of peripheral fractures [7] . It is, however, probable that the extent to which low 25(OH)D levels are associated with various conditions differs. The cut-off of 30 ng/ml is not universally agreed upon as some consider that 20 ng/ml is more appropriate [8] . It is, however, consensual to consider that a 25(OH)D level below 10 ng/ml corresponds to vitamin D deficiency because such low levels are associated with rickets and osteomalacia, the recognized diseases caused by a lack of vitamin D [1] [2] [3] [4] [5] [6] [7] [8] . In many observational studies, low 25(OH)D levels have been associated with osteopenia, cardiovascular disease, insulin resistance and diabetes, infections, cancer, renal abnormalities, inflammation and autoimmune diseases [1] [2] [3] [4] [5] [6] [7] , and with mortality in elderly people [9] , persons with high cardiovascular risk [10] , renal failure [11] , heart transplant [12] , cancer [13] and diabetes [14] . Vitamin D deficiency could be viewed only as an end-marker of bad health, but the vitamin D receptor, a member of the nuclear receptor of steroid hormones family, is widely expressed, and active vitamin D, a steroid hormone, has been involved in the physiology of numerous cell types [2, 5, 6] .
Vitamin D deficiency is frequent in HIV-infected persons [15] [16] [17] [18] [19] , even on successful combined antiretroviral therapy (cART). Factors linked to HIV infection that could contribute to decreased 25(OH)D levels include low sun exposure and alimentary intake, poor absorption, altered storage in adipose tissue, abnormal vitamin D activation due to hepatic or renal impairment, and the interference of antiretroviral drugs with vitamin D metabolism [20] . In a group of untreated HIV-infected Tanzanian women, low 25(OH)D levels was associated with the risk of mother-tochild transmission, child death, and anemia, clinical disease progression and death in the mothers [21, 22] .
In the present study, the association of 25(OH)D level with clinical disease progression was examined in a large population of HIV-infected persons from the EuroSIDA cohort, the large majority of whom were on cART.
Methods

Study population
EuroSIDA is a prospective, observational, open cohort of 16599 HIV-1-infected persons in 102 centers across 31
European countries, Israel and Argentina. The study is described in detail at www.cphiv.dk. Persons were enrolled into eight cohorts from May 1994 onwards and median follow-up is to August 2008. Data, collected on a standardized form every 6 months, include all CD4 cell counts and viral loads measured since last follow-up, starting and stopping dates of all antiretroviral drugs, dates of all AIDS-defining diagnoses using the 1993 CDC clinical definition, death, and, since 1 January 2001, non-AIDS events (cardiovascular events, non-AIDS defining malignancies, pancreatitis, end-stage renal disease and liver disease) [23] . Clinicians report ethnicity as Asian, black, white or unknown. As part of the study protocol, plasma samples are stored every 6 months.
For the present study, in order to have more than 80% power to detect a 1.5-fold increased risk of all-cause mortality or AIDS over a 5-year follow-up period, we calculated that a sample size of 2000 vitamin D measurements was necessary. The first available sample for each patient was chosen (used as baseline). Persons had to have at least 1 month follow-up prior to the earliest of AIDS or death, to have both a CD4 and viral load measurement in the 6 months prior to the sample date, and to be over 16. We randomly extracted 2001 samples from the 5435 fulfilling all these criteria, after stratification by region, to maintain regional distribution as in the complete EuroSIDA population. Among these samples, 1985 25(OH)D results were available for analysis. Characteristics of persons who were included and excluded were compared and differences examined.
Vitamin D measurement
Plasma samples were sent on dry ice from the EuroSIDA repository in Copenhagen, to the Necker Hospital, Paris, where 25(OH)D was measured in all samples in a row, blinded to persons characteristics and outcomes, by the same laboratory technician. Plasmas were processed in duplicates using the DiaSorin radioimmunassay [24] . Intra-assay and inter-assay coefficients of variation are less than 6 and 8%, respectively, throughout the whole concentration range. In 18 samples, 25(OH)D level was below the functional detection limit of 3 ng/ml and was arbitrarily given a value of 2.9 ng/ml.
Statistical methods
The persons were divided into three groups based on well accepted threshold for abnormal low levels of 25(OH)D (<10, 10-30, > 30 ng/ml) for descriptive purposes, and in tertiles for identifying factors associated with low levels of 25(OH)D and for studying the association between 25(OH)D levels and clinical outcomes. The season of the sample was defined as spring (months 3-5; Argentina: months 9-11), summer (months 6-8; Argentina: months 12, 1-2), autumn (months 9-11, Argentina: months 3-5) and winter (months 12, 1-2, Argentina: months 6-8). Characteristics of the persons in the 25(OH)D tertiles were compared using chi-squared tests for categorical variables and Kruskal-Wallis test for continuous variables. Multinomial logistic regression, using forward selection with P less than 0.1 as entry criterion was used to identify the factors associated with having a 25(OH)D level in the lowest or middle tertile, compared to the higher 25(OH)D tertile (cross-sectional analysis). Incidence rates of a new AIDS event, non-AIDS event and death (three endpoints) were calculated from the time when 25(OH)D levels were determined (i.e. baseline) and Kaplan-Meier estimation was used to determine the probability of progression within the three 25(OH)D strata. For AIDS and death, persons were followed from baseline until the development of a new AIDS event (excluding recurrences) or death, or last visit. As non-AIDS events were not collected until January 2001, analyses for this endpoint were left-censored at 1 January 2001. Poisson regression, adjusting for baseline factors, were used to assess the relationship between 25(OH)D strata and clinical progression. A sensitivity analysis further stratified the deaths into AIDS and non-AIDS related [25] : here, non-AIDS-related deaths incorporated a wider range of non-AIDS events than those collected during routine follow-up (see www.cphiv.dk).
Results
Comparison of included and excluded persons After adjustment for region, there were few differences between patients with available samples who were (n ¼ 1985) and were not (n ¼ 3450) selected for analysis. HCV antibody-positive persons were more likely to be included [adjusted odds ratio (aOR) 1.30; 95% confidence interval (CI) 1.11-1.52, P ¼ 0.0010)], as were those with a higher viral load (aOR 1.07 per log 10 higher; 95% CI 1.02-1.13, P ¼ 0.0056). Older persons were less likely to be included (aOR 0.93 per 10 years; 95% CI 0.87-0.99, P ¼ 0.016). Persons sampled during summer (aOR 0.78; 95% CI 0.66-0.92, P ¼ 0.0043), autumn (aOR 0.81; 95% CI 0.67-0.98, P ¼ 0.029) or winter (aOR 0.74; 95% CI 0.63-0.88, P ¼ 0.0005) were less likely to be included, compared to those sampled during spring.
25(OH)D levels at date of sample
Four hundred and seventy (23.7%) persons had 25(OH)D levels below 10, 1296 (65.3%) between 10 and 30, and only 219 (11%) above 30 ng/ml at baseline. For statistical analyses, the population was stratified into tertiles, which defined the following groups: below 12, 12-20 and above 20 ng/ml (Table 1) . Stratification according to tertiles will be used throughout the result section.
There was a strong influence of season, with the highest proportions of persons with a high and a low 25(OH)D level having been tested in summer and in winter, respectively. Persons infected via nonhomosexual HIV exposure, those from regions other than Southern Europe, and older persons were more likely to have a low 25(OH)D level ( Table 2 ). Dividing the sample date into quartiles, there was an increasing trend for those with later sample dates to be more likely to have a low 25(OH)D level. Compared to persons sampled in spring, those sampled in summer and autumn were less likely, whereas those sampled in winter were more likely to have low 25(OH)D levels. After adjustment for the other factors in Table 2 , compared to those of white ethnic origin, persons of a black ethnic origin (n ¼ 89) had almost four times the odds of having a 25(OH)D level in the lowest tertile (aOR 3.95; 95% CI 2.06-7.57, P < 0.0001). There was no increased odds for Asians (n ¼ 55, aOR 1.22; 95% CI 0.59-2.50, P ¼ 0.58), or for those of unknown ethnic origin (n ¼ 122, aOR 1.24; 95% CI 0.75-2.09, P ¼ 0.41). Compared to persons receiving no antiretrovirals at baseline, persons on protease inhibitor-based cART were at lower risk of having low 25(OH)D levels. No significant association was found with the use of efavirenz, nucleoside reverse transcriptase inhibitors (NRTIs) as a whole, or tenofovir.
Progression to clinical events
The event rates within the 25(OH)D strata are shown in Table 3 . Kaplan-Meier curves of progression to these endpoints are shown in Fig. 1a There were no differences between persons with 25(OH)D levels in the middle and higher tertiles. A similar trend was observed for the incidence of non-AIDS events: persons with 25(OH)D levels in the middle and higher tertiles had a nonsignificantly reduced incidence of non-AIDS events (IRR 0.73, 95% CI 0.48-1.12, P ¼ 0.16, and IRR 0.79, 95% CI 0.52-1.20, P ¼ 0.27, respectively). After adjustment, there were no significant differences in the incidence of the most frequent Deaths were stratified according to cause. Of 188 deaths, 160 were of known cause, of which 48 (30.0%) were judged to be AIDS-related and 112 (70.0%) non-AIDS related. Trends of IRR for both causes of deaths across 25(OH)D strata were consistent with those in Fig. 2 , although the lower number of events reduced the power to detect differences. Persons in the middle and higher strata had a nonsignificantly reduced incidence of AIDSrelated death (IRR 0.53, 95% CI 0.24-1.15, P ¼ 0.11, and IRR 0.61, 95% CI 0.28-1.32, P ¼ 0.21, respectively). The incidence of non-AIDS-related death was nonsignificantly reduced for persons with 25(OH)D values in the middle tertile (IRR 0.67, 95% CI 0.41-1.09, P ¼ 0.10), but significantly reduced for those with values in the higher tertile (IRR 0.60, 95% CI 0.37-0.98, P ¼ 0.043).
There was no evidence of an interaction between race and 25(OH)D tertile and any of the clinical events (P>0.1), although this analysis had limited power because Body mass index (BMI) was available for 1518 persons within 6 months of baseline, and there was no correlation with 25(OH)D levels (correlation coefficient 0.016, P ¼ 0.53). After adjustment, compared to those with medium BMI, persons with a low BMI (<18) had marginally increased odds of having a 25(OH)D level in the lowest tertile (aOR 1.71; 95% CI 0.92-3.17, P ¼ 0.091), and persons with a high BMI (>25) had similar odds of having a 25(OH)D level in the lowest tertile (aOR 1.02; 95% CI 0.79-1.32, P ¼ 0.88). Table 2 . Factors associated with having 25(OH)D levels in the lowest and middle tertiles, as compared to higher 25(OH)D tertile (>20 ng/ml), at baseline. Except for Argentina, where seasons were defined as spring (months 9-11), summer (months 12, 1-2), autumn (months 3-5) and winter (months 6-8). 
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Discussion
The study examined 25(OH)D levels in a large population of well characterized HIV-infected persons.
The objectives were to describe the prevalence and correlates of vitamin D deficiency, and to determine whether a 25(OH)D level was associated with subsequent all-cause death, AIDS-defining or non-AIDS events.
The present results confirm [15] [16] [17] [18] [19] that vitamin D insufficiency or deficiency is frequent in HIV-infected persons. Studies across Europe have found highly variable 25(OH)D levels in the general population, with levels below 10 ng/ml in 2-30% of adults [26] . In the US, 25(OH)D levels below 30 ng/ml and below 20 ng/ml were similarly prevalent in the SUN cohort of HIVinfected persons vs. in the general population (NHANES study), after adjustment for age, sex and race: 70.3 vs. 79.1% and 29.7 vs. 38.8%, respectively [27] . Therefore, vitamin D deficiency might not be more frequent in people living with HIV than in the general population. Unsurprisingly, the season of sampling was associated with 25(OH)D levels, and persons with less, or benefiting less from, sun exposure (living outside Southern Europe and Argentina, or of black ethnic origin) were more likely to have very low 25(OH)D levels. Nonhomosexual route of HIV-1 transmission was also associated with lower 25(OH)D levels. This is in agreement with an earlier study suggesting that intravenous drug use is a risk factor for low 25(OH)D [18] . Of note, the association with heterosexual transmission remained after adjustment for ethnicity. These differences across transmission groups may reflect other factors we were not able to adjust for, such as nutrition and sun exposure. As in the general population, increasing age was also associated with lower 25(OH)D levels. Exposure to cART [19] and the use of efavirenz [17, 18, 28, 29] have been associated with lower 25(OH)D levels, but we were unable to reproduce this finding in the present study. Neither the use of NRTIs or protease inhibitors was associated with lower levels of 25(OH)D. The finding that protease inhibitor use was associated with higher 25(OH)D levels, as also shown in the SUN cohort [27] , is of unclear biological relevance.
Having a 25(OH)D level in the lowest tertile (<12 ng/ ml) was strongly associated with the occurrence of AIDS events and all-cause mortality over a median follow-up of 5 years, after adjusting for a large number of variables, including season, ethnic and geographic origin, CD4 cell count and viral load (at baseline and time-adjusted), and there was no interaction between these variables and 25(OH)D levels for the association with events. Thus, a very low 25(OH)D level was associated with events, even in the case of virologically controlled HIV infection and immune restoration. The prognostic value of vitamin D deficiency was also independent of anemia, another prognostic factor of HIV infection [30] , that has been associated with low 25(OH)D levels in untreated HIVinfected African women [20] . In addition, although we only had information on a subgroup of persons, low 25(OH)D levels were not correlated with low eGFR, an indicator of cardiovascular risk in the general and HIVinfected populations [31] , associated with all-cause and cardiovascular mortality [32] .
We thus found a strong association between the lowest 25(OH)D tertile (<12 ng/ml) and the two main endpoints of all-cause death and AIDS events, but no differences between the medium and high 25(OH)D tertiles. Vitamin D deficiency therefore represents a new, independent, unfavorable prognostic marker in HIV infection, but without further research this cannot translate into clinical recommendations. [33] . Studies have also associated vitamin D insufficiency with hypertension, insulin resistance and high BMI, thus establishing a link with cardiovascular risk [2] , clinical cardiovascular disease [34, 35] , and cardiovascular and all-cause death [10, 14] . Vitamin D regulates endothelial function [36] , downregulates the renin gene activity [37] , and a placebocontrolled trial has shown that vitamin D administration lowers blood pressure in hypertensive persons [38] . Vitamin D has regulatory effects on immune functions [39] : the vitamin D receptor is expressed on adaptive and innate immune cells; vitamin D plays a role in innate immunity, particularly in the defence against mycobacteria, and in T-cell activation, with vitamin D insufficiency leading to altered T-cell proliferation [40] . Vitamin D deficiency has also been associated with inflammation [41] . In a study of patients referred for a coronary angiography, vitamin D deficiency was associated with all-cause and cardiovascular mortality, and correlated with high levels of markers of cell adhesion, oxidative stress and inflammation [C-reactive protein (CRP) and interleukin 6 (IL-6)] [10] . In a placebocontrolled study, vitamin D supplementation lowered the level of the inflammatory cytokine TNF-a and increased the level of the anti-inflammatory cytokine IL-10, in patients with congestive heart failure [42] . In a large cohort, low vitamin D levels have also been associated with increased levels of the coagulation activation markers tissue plasminogen activator and D-dimer [43] .
Taken together, these results are of particular relevance to our findings, because of the well described increased vascular risk in HIV-infected persons, and because markers of inflammation (CRP and IL-6) and coagulation activation (D-dimers) have been associated with mortality and opportunistic diseases in HIV-infected persons [44, 45] . In the present study, whereas non-AIDS events were not significantly associated with low 25(OH)D (possibly due to a lack of power), non-AIDS deaths were: this could reflect an aggravating effect of vitamin D deficiency, possibly linked with immune dysfunction or increased inflammation, on different conditions.
The study has several limitations. The study population may not be representative of the whole cohort, with excluded persons being older and having been sampled during spring less often: however, this would only attenuate the effect of 25(OH)D level on events. There were also a relatively low number of non-AIDS events: the impact of vitamin D on these events should therefore be addressed in larger studies. J.-P.V., J.-C.S., O.K., J.D.L., and A.M. designed the study, planned the analyses and wrote the first draft of the manuscript. They had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. J.-C.S. supervised vitamin D measurements. A.M. and J.R. performed the statistical analyses. B.K., M.L., J.G., C.P., J.R.B. contributed major suggestions for analysis and participated in the writing of the manuscript. All clinicians enrolled persons in the study and collected data.
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